The KRAS targeting revolution in metastatic pancreatic cancer
A new drug doubled survival time for advanced pancreatic cancer patients, offering hope for those with limited prior treatment options.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Risk of Dementia after initiation of GLP-1 RA versus long-acting…
People with type 2 diabetes taking GLP-1 drugs showed 36% lower dementia risk than those on insulin, suggesting broader brain benefits.
Promising but preliminaryAPOE and genetic risk variants influence Alzheimer's disease onset in…
Genetic variants controlling dementia onset span up to a decade, revealing how biology shapes timing and opening doors for targeted prevention.
Promising but preliminaryDurable clinical and immunologic response to an off-the-shelf…
A personalized cancer vaccine kept a patient with advanced Ewing sarcoma stable for over two years by training immune cells to recognize tumor markers.
Promising but preliminaryThe thrombopoietin receptor in myeloproliferative neoplasms
Scientists pinpointed the shared molecular hub driving three blood cancers, potentially unlocking new treatment strategies across these diseases.